《大行報告》里昂下調思摩爾(06969.HK)目標價至24元 評級「買入」
里昂發表報告,將思摩爾(06969.HK)2022年至2024年淨利潤預測下調8%,以反映一次性封閉式產品對毛利率的攤薄。該行重申其「買入」評級,將目標價從25元小幅下調至24元。
思摩爾在2022年英國電子煙展覽會上推出全球首款陶瓷芯一次性霧化解決方案FEELM Max。該行預計一次性電子煙產品將在今年下半年有顯著的訂單交付,同時在下半年在歐洲、韓國和日本推出FEELM Air技術。該行大致維持2022年至24年收入預測,反映中國電子煙標準政策實施延遲至今年10月1日,及電子煙零售牌照發放好於預期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.